NCT00839007View on ClinicalTrials.gov

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions
Acute Decompensated Heart Failure
Interventions
DRUG

CD-NP

Infusion of CD-NP at one of up to 6 doses or placebo

Trial Locations (21)

10467

The Bronx

12351

Berlin

13100

Safed

13353

Berlin

16100

Nazareth

31096

Haifa

32216

Jacksonville

33149

Miami Beach

41464

Neuss

44137

Dortmund

48201

Detroit

49100

Petah Tikva

52246

Iowa City

55415

Minneapolis

60611

Chicago

64239

Tel Aviv

77030

Houston

78278

Ashkelon

90033

Los Angeles

90509

Torrance

97080

Würzberg

Sponsors

Lead Sponsor

Nile Therapeutics
All Listed Sponsors
lead

Nile Therapeutics

INDUSTRY

NCT00839007 - Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure | Biotech Hunter | Biotech Hunter